ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,582.95
      1.12%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. NexImmune Inc (NEXI)

      7. NexImmune Inc (NEXI) News

      NEXI

      NexImmune (NEXI)

      NexImmune Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NEXI
      DateTimeSourceHeadlineSymbolCompany
      03/07/20241:20PMBusiness WireKonzernergebnis zum 31. Dezember 2023 genehmigt, starke Margenausweitung und Liquiditätsüberschuss von 601 Millionen Euro, Aktienrückkaufprogramm von 500 Millionen EuroNASDAQ:NEXINexImmune Inc
      03/07/202412:33PMBusiness WireApprobation des résultats financiers du groupe au 31 décembre 2023 ; forte expansion de la marge et génération d'excédents de trésorerie à hauteur de 601 millions d’euros ; programme de rachat d’actions de 500 millions d’eurosNASDAQ:NEXINexImmune Inc
      03/07/20241:31AMBusiness WireApprovati i risultati finanziari di Gruppo al 31 dicembre 2023, Forte espansione dell’EBITDA margin ed excess cash generation a € 601 milioni, € 500 milioni per acquisto di azioni proprieNASDAQ:NEXINexImmune Inc
      03/07/20241:30AMBusiness WireGroup Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back ProgramNASDAQ:NEXINexImmune Inc
      02/06/20244:42PMGlobeNewswire Inc.NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NEXINexImmune Inc
      02/06/20244:30PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NEXINexImmune Inc
      02/05/20245:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
      02/05/20244:34PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NEXINexImmune Inc
      02/02/20242:00PMGlobeNewswire Inc.NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NEXINexImmune Inc
      02/02/20241:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
      02/01/20249:17AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
      01/19/20244:43PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
      01/18/20244:43PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NEXINexImmune Inc
      12/22/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
      12/01/20231:39PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
      11/22/20235:40PMEdgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:NEXINexImmune Inc
      11/22/20235:34PMEdgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:NEXINexImmune Inc
      11/22/20235:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NEXINexImmune Inc
      11/21/20234:39PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NEXINexImmune Inc
      11/20/20235:19PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NEXINexImmune Inc
      11/20/20235:01PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NEXINexImmune Inc
      11/17/20234:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NEXINexImmune Inc
      11/15/20234:17PMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:NEXINexImmune Inc
      11/09/20235:47PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NEXINexImmune Inc
      11/09/20239:35AMBusiness WireFinanzergebnisse der Gruppe zum 30. September 2023 bestätigen solide finanzielle Leistung im Rahmen des Plans und kontinuierliche Ausweitung der EBITDA-MargeNASDAQ:NEXINexImmune Inc
      11/09/20238:52AMBusiness WireLes résultats financiers du groupe au 30 septembre 2023 ont été approuvés, croissance solide conforme au plan, avec une augmentation continue de la marge de BAIIANASDAQ:NEXINexImmune Inc
      11/09/20231:30AMBusiness Wire Group Financial Results as of September 30th 2023 Approved Solid Growth Performance in Line With Plan, With Continued EBITDA Margin ExpansionNASDAQ:NEXINexImmune Inc
      11/09/20231:30AMBusiness WireApprovati I Risultati Finanziari Di Gruppo Al 30 Settembre 2023 Solida Performance in Linea Con I Piani E Continua Crescita Dell’EBITDA MarginNASDAQ:NEXINexImmune Inc
      11/02/20235:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
      11/02/20234:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
       Showing the most relevant articles for your search:NASDAQ:NEXI